{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05877963",
            "orgStudyIdInfo": {
                "id": "TG1101-RMS401"
            },
            "organization": {
                "fullName": "TG Therapeutics, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study to Evaluate Efficacy When Transitioning From a Current Disease Modifying Therapy (DMT) to Ublituximab",
            "officialTitle": "Evaluating Efficacy When Transitioning From a Current Disease Modifying Therapy (DMT) to Ublituximab (ENHANCE)",
            "acronym": "ENHANCE",
            "therapeuticArea": [
                "Other"
            ],
            "study": "study-to-evaluate-efficacy-when-transitioning-from-a-current-disease-modifying-therapy-dmt-to-ublituximab"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-06-13",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-06-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-06-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-05-18",
            "studyFirstSubmitQcDate": "2023-05-18",
            "studyFirstPostDateStruct": {
                "date": "2023-05-26",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-18",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-19",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "TG Therapeutics, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The primary purpose of this phase 3b study is to assess efficacy after transition from a current DMT to ublituximab, as measured by T1 Gadolinium (Gd)-enhancing lesions."
        },
        "conditionsModule": {
            "conditions": [
                "Relapsing Multiple Sclerosis"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 300,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Ublituximab",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will be transitioned from current anti-CD20 therapy or other DMT to receive ublituximab 450 milligram (mg) or 150 mg intravenous (IV) infusion on Day 1 of Week 1 (W1D1) and ublituximab 450 mg IV infusion at D15 (if applicable) and Week 24.",
                    "interventionNames": [
                        "Biological: Ublituximab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "Ublituximab",
                    "description": "Administered as an IV infusion.",
                    "armGroupLabels": [
                        "Ublituximab"
                    ],
                    "otherNames": [
                        "TG-1101",
                        "BRIUMVI"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Percentage of Participants With No Change or Reduction in Number of T1 Gd-Enhancing Lesions From Baseline to Week 48",
                    "description": "The Gd-enhancing T1 lesions will be evaluated using magnetic resonance imaging (MRI) technique.",
                    "timeFrame": "Baseline up to Week 48"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Percentage of Participants Free of T1 Gd-Enhancing Lesions",
                    "description": "The Gd-enhancing T1 lesions will be evaluated using MRI technique.",
                    "timeFrame": "Week 48"
                },
                {
                    "measure": "Percentage of Participants Experiencing Infusion Related Reactions (IRRs)",
                    "description": "IRRs are defined as infusion related adverse events (AEs) that occur within one day of an infusion and resolve within 7 days. IRRs will be reported by investigator.",
                    "timeFrame": "Up to Week 48"
                },
                {
                    "measure": "Treatment Satisfaction Questionnaire for Medication (TSQM-9) Scores",
                    "description": "The TSQM-9 is a 9-item questionnaire with 3 domains: Satisfaction, convenience, and effectiveness.",
                    "timeFrame": "Weeks 24 and 48"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of RMS (2017 Revised McDonald criteria).\n* Participants currently treated with ocrelizumab, rituximab, ofatumumab.\n* Participants that are currently being treated with other selected DMTs.\n* Expanded Disability Status Scale (EDSS) score \u2264 5.5 at screening.\n* Neurologically stable for \\> 30 days prior to first dose of ublituximab.\n\nExclusion Criteria:\n\n* Suboptimal response to anti-CD20 therapy in the prior 6 months defined as\n\n  1. Documented MRI worsening (\u2265 2 active T1-weighted Gd-enhancing lesions, any new or enlarging T2 lesions and/or\n  2. Clinical worsening as measured by EDSS or meaningful change in clinical measure\n* Relapse within the 12 months prior to W1D1.\n* History of any Grade \\> 3 Infusion Related Reaction (IRR) on prior anti-CD20 therapy.\n* Primary-progressive multiple sclerosis (PPMS) or inactive Secondary Progressive MS (SPMS).\n* Active chronic (or stable but treated with immune therapy) disease of the immune system other than MS (e.g., rheumatoid arthritis, scleroderma, Sj\u00f6gren's syndrome, Crohn's disease, ulcerative colitis, etc.) or immunodeficiency syndrome (hereditary immune deficiency, drug-induced immune deficiency, etc.).\n* Current evidence or known history of clinically significant infection, including: chronic, recurrent, or ongoing active viral, bacterial, or fungal infectious disease requiring long term systemic treatment such as, but not limited to chronic urinary tract infection, chronic pulmonary infection with bronchiectasis, tuberculosis, or active hepatitis C virus (HCV).\n* Previous serious opportunistic or atypical infection.\n* Evidence of chronic active or history of hepatitis B virus (HBV) infection as evidenced by a detectable hepatitis B surface antigen (HBsAg), or positive hepatitis B core antibody (HBcAb), or chronic hepatitis C infection. Participants with positive hepatitis C virus antibody (HCV Ab) are eligible only if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA).\n* History or evidence (clinical, radiological, or biomarker) of suspected or confirmed progressive multifocal leukoencephalopathy (PML).\n* Receipt of any live or live-attenuated vaccines (including vaccines for varicella-zoster virus or measles) within 4 weeks prior to first study drug administration.\n* Participants requiring treatment with intravenous immune globulin (IVIG) for decreased immunoglobulins within the 12 months prior to W1D1.\n* Any active malignancies other than adequately treated basal, squamous cell or in situ carcinoma.\n* Participants who have ever received ublituximab, alemtuzumab, cyclophosphamide, mitoxantrone, cladribine, or daclizumab (including for non-MS indications).",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "65 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "TG Therapeutics Clinical Support Team",
                    "role": "CONTACT",
                    "phone": "1-877-555-8489",
                    "email": "clinicalsupport@tgtxinc.com"
                }
            ],
            "locations": [
                {
                    "facility": "TG Therapeutics Investigational Trial Site",
                    "status": "RECRUITING",
                    "city": "Birmingham",
                    "state": "Alabama",
                    "zip": "35209",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.52066,
                        "lon": -86.80249
                    }
                },
                {
                    "facility": "TG Therapeutics Investigational Trial Site",
                    "status": "RECRUITING",
                    "city": "Cullman",
                    "state": "Alabama",
                    "zip": "35058",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.17482,
                        "lon": -86.84361
                    }
                },
                {
                    "facility": "TG Investigational Site",
                    "status": "RECRUITING",
                    "city": "Fort Collins",
                    "state": "Colorado",
                    "zip": "80528",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.58526,
                        "lon": -105.08442
                    }
                },
                {
                    "facility": "TG Therapeutics Investigational Trial Site",
                    "status": "RECRUITING",
                    "city": "Washington",
                    "state": "District of Columbia",
                    "zip": "20007",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.89511,
                        "lon": -77.03637
                    }
                },
                {
                    "facility": "TG Therapeutics Investigational Trial Site",
                    "status": "RECRUITING",
                    "city": "Tampa",
                    "state": "Florida",
                    "zip": "33612",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 27.94752,
                        "lon": -82.45843
                    }
                },
                {
                    "facility": "TG Therapeutics Investigational Trial Site",
                    "status": "RECRUITING",
                    "city": "Indianapolis",
                    "state": "Indiana",
                    "zip": "46256",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.76838,
                        "lon": -86.15804
                    }
                },
                {
                    "facility": "TG Therapeutics Investigational Trial Site",
                    "status": "RECRUITING",
                    "city": "Lutherville",
                    "state": "Maryland",
                    "zip": "21093",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.42122,
                        "lon": -76.62608
                    }
                },
                {
                    "facility": "TG Therapeutics Investigational Trial Site",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "70809",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "TG Therapeutics Investigational Trial Site",
                    "status": "RECRUITING",
                    "city": "Foxboro",
                    "state": "Massachusetts",
                    "zip": "02035",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.06538,
                        "lon": -71.24783
                    }
                },
                {
                    "facility": "TG Investigational Site",
                    "status": "RECRUITING",
                    "city": "Farmington",
                    "state": "Michigan",
                    "zip": "48334",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.46448,
                        "lon": -83.37632
                    }
                },
                {
                    "facility": "TG Therapeutics Investigational Trial Site",
                    "status": "RECRUITING",
                    "city": "Golden Valley",
                    "state": "Minnesota",
                    "zip": "55422",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 45.00969,
                        "lon": -93.34912
                    }
                },
                {
                    "facility": "TG Therapeutics Investigational Trial Site",
                    "status": "RECRUITING",
                    "city": "Plymouth",
                    "state": "Minnesota",
                    "zip": "55446",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 45.01052,
                        "lon": -93.45551
                    }
                },
                {
                    "facility": "TG Therapeutics Investigational Trial Site",
                    "status": "RECRUITING",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63131",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                },
                {
                    "facility": "TG Therapeutics Investigational Trial Site",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10025",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "TG Therapeutics Investigational Trial Site",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "11021",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "TG Therapeutics Investigational Trial Site",
                    "status": "RECRUITING",
                    "city": "Raleigh",
                    "state": "North Carolina",
                    "zip": "27607",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.7721,
                        "lon": -78.63861
                    }
                },
                {
                    "facility": "TG Therapeutics Investigational Trial Site",
                    "status": "RECRUITING",
                    "city": "Oklahoma City",
                    "state": "Oklahoma",
                    "zip": "73104",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.46756,
                        "lon": -97.51643
                    }
                },
                {
                    "facility": "TG Therapeutics Investigational Trial Site",
                    "status": "RECRUITING",
                    "city": "Knoxville",
                    "state": "Tennessee",
                    "zip": "37922",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.96064,
                        "lon": -83.92074
                    }
                },
                {
                    "facility": "TG Therapeutics Investigational Trial Site",
                    "status": "RECRUITING",
                    "city": "Salt Lake City",
                    "state": "Utah",
                    "zip": "84103",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.76078,
                        "lon": -111.89105
                    }
                },
                {
                    "facility": "TG Therapeutics Investigational Trial Site",
                    "status": "RECRUITING",
                    "city": "Vienna",
                    "state": "Virginia",
                    "zip": "22182",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.90122,
                        "lon": -77.26526
                    }
                },
                {
                    "facility": "TG Therapeutics Investigational Trial Site",
                    "status": "RECRUITING",
                    "city": "Kirkland",
                    "state": "Washington",
                    "zip": "98034",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 47.68149,
                        "lon": -122.20874
                    }
                },
                {
                    "facility": "TG Therapeutics Investigational Trial Site",
                    "status": "RECRUITING",
                    "city": "Seattle",
                    "state": "Washington",
                    "zip": "98109",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 47.60621,
                        "lon": -122.33207
                    }
                },
                {
                    "facility": "TG Therapeutics Investigational Trial Site",
                    "status": "RECRUITING",
                    "city": "Spokane",
                    "state": "Washington",
                    "zip": "99208",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 47.65966,
                        "lon": -117.42908
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009103",
                    "term": "Multiple Sclerosis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000020278",
                    "term": "Demyelinating Autoimmune Diseases, CNS"
                },
                {
                    "id": "D000020274",
                    "term": "Autoimmune Diseases of the Nervous System"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000003711",
                    "term": "Demyelinating Diseases"
                },
                {
                    "id": "D000001327",
                    "term": "Autoimmune Diseases"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12060",
                    "name": "Multiple Sclerosis",
                    "asFound": "Multiple Sclerosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M15415",
                    "name": "Sclerosis",
                    "relevance": "LOW"
                },
                {
                    "id": "M4629",
                    "name": "Autoimmune Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M22098",
                    "name": "Demyelinating Autoimmune Diseases, CNS",
                    "relevance": "LOW"
                },
                {
                    "id": "M22094",
                    "name": "Autoimmune Diseases of the Nervous System",
                    "relevance": "LOW"
                },
                {
                    "id": "M6909",
                    "name": "Demyelinating Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        }
    },
    "hasResults": false
}